This is the authors' abstract. We don't add key points for this paper.
Despite recent advances in our understanding of the biological basis of prostate cancer, the management of the disease, especially in the castration-resistant phase, remains a significant challenge. Deregulation of the phosphatidylinositol 3-kinase (PI3K) pathway is increasingly implicated in a number of malignancies, including prostate carcinogenesis. In this review, we detail the role of this pathway in the pathogenesis of prostate cancer and the therapeutic implications of targeting it.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Elfiky et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: